Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OKI 422

Next Previous
Drug Profile

OKI 422

Alternative Names: KDAc-0001; OKI-422

Latest Information Update: 21 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Broad Institute
  • Developer OnKure Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action HDAC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 21 Apr 2023 Discontinued - Preclinical for Non-Hodgkin's lymphoma in USA (unspecified route) (OnKure Therapeutics pipeline, January 2023)
  • 23 Jul 2019 KDAc Therapeutics and OnKure enter into license and option agreement for KDAc 0001
  • 23 Jul 2019 KDAc in-licenses KDAc 0001 from the Broad Institute before July 2019

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top